Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 1.56B +513.0% |
| Revenue (ttm) | n/a |
| Net Income | -49.30M |
| EPS | -4.19 |
| Shares Out | 14.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 374,164 |
| Open | 112.00 |
| Previous Close | 114.82 |
| Day's Range | 105.62 - 114.48 |
| 52-Week Range | 20.20 - 151.18 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 229.56 (+111.25%) |
| Earnings Date | May 7, 2026 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for PVLA stock is "Strong Buy." The 12-month stock price target is $229.56, which is an increase of 111.25% from the latest price.
News
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
Palvella Therapeutics (PVLA) announced completion of its pre-new drug application meeting with FDA for Qtorin 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations. The pre-NDA meeting a...
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleed...
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
Palvella Therapeutics (PVLA) announced the issuance of U.S. Patent No. 12,636,273 by the United States Patent and Trademark Office. The issued patent, exclusively licensed by Palvella from Yale Univer...
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP)
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializin...
Palvella Therapeutics announces new data from SELVA, TOIVA studies
Palvella Therapeutics (PVLA) announced new clinical data from the Phase 3 SELVA and Phase 2 TOIVA studies were reported at the International Society for the Study of Vascular Anomalies World…
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Microcystic Lymphatic Malformation Investigator Global Asses...
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
Palvella Therapeutics (PVLA) announced new data from the Phase 2 TOIVA trial of Qtorin rapamycin in patients with cutaneous venous malformations were presented at the 83rd Annual Meeting of the…
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) a...
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations
Palvella Therapeutics initiated with an Overweight at Stephens
Stephens initiated coverage of Palvella Therapeutics (PVLA) with an Overweight rating and $220 price target Palvella is a clinical-stage biopharmaceutical company leveraging its Qtorin platform to tar...
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
Reports Q1 cash, cash equivalents and short-term investments were $261.9M as of March 31, 2026. Reports Q1 R&D expenses $9.3M vs $4.1M last year. Reports Q1 G&A expenses $5.5M vs…
Palvella Therapeutics Earnings Call Transcript: Q1 2026
Positive phase III results for QTORIN rapamycin in mLM and a $230M financing position the company for a potential first FDA approval and U.S. launch in 2027, with a robust pipeline and strong physician support for first-line use.
Palvella Therapeutics Earnings release: Q1 2026
Palvella Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Palvella Therapeutics Quarterly report: Q1 2026
Palvella Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Palvella Therapeutics Slides: Q1 2026
Palvella Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tr...
Palvella Therapeutics doses first patients in LOTU trial
Palvella Therapeutics (PVLA) announced that the first patients have been dosed in LOTU, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of Qtorin 3.9% rapamycin…
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.
Palvella Therapeutics Proxy statement: Proxy filing
Palvella Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Palvella Therapeutics Proxy statement: Proxy filing
Palvella Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET
Palvella Therapeutics Appoints John D. Doux, M.D.
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership